Back to search results

Pneumonia Vaccine Response in Esophageal Cancer Patients After Chemoradiation

This study is looking at how well people with esophageal cancer respond to a pneumonia vaccine (pneumococcal vaccination) after they've had chemoradiation (a combination of chemotherapy and radiation therapy). Specifically, it wants to see if a severe drop in white blood cells called lymphocytes (Grade IV lymphopenia) due to radiation affects how well your body makes protective antibodies after the vaccine. You may be able to join if you are an adult receiving, planning to receive, or have recently completed chemoradiation for esophageal cancer using either proton therapy or intensity-modulated radiation therapy (IMRT). The main goal is to understand how chemoradiation impacts your immune response to the pneumonia vaccine. The study is currently unclear on its recruitment status.

Study design
This is an observational study, meaning researchers will watch and collect information without giving new treatments. It plans to include about 80 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will follow participants to measure their vaccine response for an average of 1 year, through study completion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06181656

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~80 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:Pneumonia vaccine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination
Measured over through study completion; an average of 1 year

Conditions

Pneumococcal Vaccine
Esophageal Cancer
Lymphopenia
Chemoradiation

Explore related trials

Esophageal CarcinomaHealthy VolunteersLiver Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Steven H Lin, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Steven H Lin, MD
[email protected]
(713) 563-8490
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Patients with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., Human immunodeficiency virus (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy
Patients receiving intravenous immunoglobulin (IVIG) during the study or in the three months prior to study enrollment.
Patients with psychiatric illness/social situations that would limit compliance with study requirements.
Individuals with previous pneumococcal vaccination in the last 5 years.
Individuals with severe allergy to any of the vaccine components

What this trial measures

  • Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccinationthrough study completion; an average of 1 year

    Serologic responses will be calculated as the average fold change in antibody titer for each of 20 pneumococcal serotypes between baseline (time 0) and the first post-vaccination blood draw.